Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Position Lowered by First Trust Advisors LP

First Trust Advisors LP lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 32.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 311,785 shares of the biotechnology company’s stock after selling 153,131 shares during the quarter. First Trust Advisors LP’s holdings in Sarepta Therapeutics were worth $37,910,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC raised its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics during the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 216 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $61.76 on Friday. The stock has a market cap of $5.99 billion, a P/E ratio of 49.41 and a beta of 0.93. The stock’s 50-day moving average price is $78.22 and its two-hundred day moving average price is $106.20. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $48.01 and a 1 year high of $173.25.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares of the company’s stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on SRPT shares. Deutsche Bank Aktiengesellschaft decreased their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Scotiabank cut their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Needham & Company LLC reduced their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday, April 3rd. Royal Bank of Canada cut Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. Finally, Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a research report on Friday, April 11th. They issued an “overweight” rating and a $115.00 price objective for the company. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.